SLNO: Class Action Looms as Hyperphagia Drug Launch Hits Snag

Introduction

Soleno Therapeutics (NASDAQ: SLNO) is a rare-disease biotech whose fortunes hinge on VYKAT™ XR (diazoxide choline), the first FDA-approved treatment for hyperphagia in Prader–Willi syndrome (PWS) (www.fiercepharma.com). The drug’s March 2025 approval was a milestone that sent Soleno’s stock up 37–38% in a day to multi-year highs (www.fiercepharma.com), reflecting optimism for addressing PWS patients’ insatiable hunger. However, the highly anticipated launch has hit a major snag. Emerging safety concerns and a short-seller’s allegations disrupted the rollout, eroding investor confidence and now leading to securities class action claims that Soleno misled shareholders. Below is a timeline of the key developments illustrating how a triumphant FDA win turned into legal and operational turmoil:

– Mar 26–27, 2025: FDA Approval and Surge. Soleno’s VYKAT XR wins FDA approval as the first therapy for PWS hyperphagia (www.fiercepharma.com). Shares jump ~38%, reaching their highest level in 8+ years (www.bloomberg.com), as the company prepares to launch in April. – Aug 15, 2025: Short-Seller Allegations Surface. Activist short fund Scorpion Capital publishes an “exposé” questioning Soleno’s trial data integrity and flagging safety red flags – including reports of children on VYKAT XR hospitalized with signs of heart failure (www.prnewswire.com). The report claims Soleno downplayed these risks and inflated launch metrics, triggering a ~12% two-day stock drop (robbinsllp.com). – Sep 10, 2025: Patient Death Disclosed. Soleno files an 8-K revealing that a patient died after taking VYKAT XR, heightening safety fears (robbinsllp.com). The stock plunges ~19% over the next two sessions (robbinsllp.com) as investors grapple with the fatality’s implications. – Nov 4–5, 2025: Launch “Disruption” & Stock Plunge. In its Q3 earnings call, management acknowledges that the August short-seller controversy caused a “disruption in our launch trajectory” – fewer new patient start forms and more drop-outs after the report’s release (www.prnewswire.com). The next day, Soleno’s share price collapses ~27% (from ~$64 to ~$47) (robbinsllp.com) as the company’s “disappointing” update rattles the market (www.prnewswire.com). – Mar 2026: Class Action Filed. Shareholder rights firms (Hagens Berman, Robbins LLP, and others) announce a securities class action lawsuit on behalf of investors who bought SLNO from Mar 26 to Nov 4, 2025 (www.prnewswire.com) (robbinsllp.com). The complaint alleges Soleno misrepresented DCCR/VYKAT XR’s safety and viability, given the above events.

This report examines Soleno’s financial position and policies, current valuation, and the growing risks and red flags now confronting the company.

Dividend Policy and Shareholder Returns

Soleno Therapeutics has never paid a cash dividend, reflecting its history as a development-stage biotech with consistent net losses until 2025. Management has instead favored reinvesting in R&D and commercialization, only recently shifting toward shareholder returns after turning profitable. Notably, in November 2025 – amid share price volatility – Soleno’s board approved a $100 million accelerated share repurchase (ASR) program (www.globenewswire.com). This buyback was completed by year-end 2025, signaling confidence and directly returning capital to shareholders. The stock’s dividend yield remains 0%, and no dividend initiation has been indicated. Going forward, any excess cash return is likely to occur via opportunistic buybacks rather than dividends, until the company’s earnings stabilize over multiple years.

Leverage, Debt Maturities, and Coverage

Soleno entered its commercial phase with a strong cash hoard and a flexible debt facility. In December 2024, anticipating the VYKAT XR launch, the company secured a loan agreement with Oxford Finance for up to $200 million in financing (investors.soleno.life). Key terms of this debt package are:

– Initial Draw: $50 million was drawn at closing (Dec 2024) to bolster liquidity (investors.soleno.life), with an additional $100 million available in future tranches contingent on FDA approval (since achieved) and certain commercial milestones. A final $50 million tranche is subject to mutual consent (investors.soleno.life). – Interest Rate & Term: The loan carries interest-only payments for 48 months, with a 60-month total term (extendable by 12 months if performance milestones are met by Sept 30, 2026) (investors.soleno.life). The interest rate is floating at one-month SOFR + 5.50%, equating to roughly 10–11% currently (investors.soleno.life). No principal repayment is due until late 2028, and maturity will occur in late 2029 (or 2030 if the extension triggers). – Cash Position: Soleno’s cash and investments totaled $506.1 million as of Dec 31, 2025 (www.globenewswire.com), thanks to successful equity raises and initial VYKAT XR sales. This vastly exceeds the $50 million debt outstanding, leaving the company in a net cash position. Even after funding the $100M buyback, Soleno retained over half a billion in liquidity (www.globenewswire.com) for operations and growth. – Coverage: Given its cash buffer and newly positive cash flow, Soleno can comfortably cover debt service. In 2025 the company incurred ~$5.5 million in interest expense (www.globenewswire.com), easily offset by ~$17 million in interest income earned on its large cash balance (www.globenewswire.com). With VYKAT XR now generating operating profits, interest coverage is strong. Unless Soleno draws significantly more debt, leverage remains low – providing financial flexibility as the company navigates its current challenges.

Financial Performance and Valuation

Initial Commercial Traction: VYKAT XR’s rollout delivered robust early results. From the late-March 2025 approval through year-end, net product revenue reached $190.4 million (www.globenewswire.com), an impressive figure given only nine months on the market. Soleno reported $91.7 million in Q4 2025 sales alone (www.globenewswire.com), more than doubling Q2’s ~$33 million after launch (www.fiercepharma.com). This rapid uptake pushed Soleno into profitability: 2025 net income was $20.9 million, a sharp turnaround from a $175.9 million loss in 2024 (www.fool.com). Cash flow also turned positive, with $48.7 million generated from operations in Q4 (www.globenewswire.com). These results reflect pent-up demand in the PWS community and the drug’s ultra-premium pricing (approximately $466,200 per patient annually on average weight dosing) (www.fiercepharma.com).

Patient and Prescriber Metrics: By December 31, 2025, Soleno had received 1,250 patient start forms, of which 859 patients remained on active therapy (www.globenewswire.com). This suggests VYKAT XR had already reached roughly 12.5% of the U.S. addressable PWS market in under a year (www.globenewswire.com). Prescriber adoption was also broad-based, with 630 unique physicians having prescribed the drug (www.globenewswire.com). Importantly, insurance coverage ramped quickly – policies encompassing over 185 million U.S. lives now cover VYKAT XR (www.globenewswire.com) – indicating that payors have largely recognized the unmet need and are willing to reimburse despite the high cost. These strong key performance indicators in 2025 paint a picture of a product with substantial initial demand in a rare disease population of perhaps ~10,000 patients nationally.

Share Price Performance: Soleno’s stock reflected the company’s roller-coaster year. The FDA approval in March 2025 and subsequent commercial momentum drove euphoric gains – the stock soared into the mid-$60s by late 2025 (robbinsllp.com) from the sub-$20 levels pre-approval, as investors anticipated a rare-disease blockbuster. However, safety scares and the Q3 launch hiccups reversed some of these gains (see Timeline above). After the November 2025 plunge, SLNO traded in the $40 range by early 2026. As of late February 2026, shares hovered around $41, equating to a $2.1 billion market cap (www.fool.com). The stock remains well above pre-approval levels but below its 2025 peak, reflecting a market reassessment of risk versus reward.

Valuation: At ~$40–$41 per share, Soleno’s valuation hinges on significant growth expectations tempered by recent risks. The current enterprise value (market cap minus net cash) is roughly $1.6–$1.7 billion, about 8.5× Soleno’s 2025 sales. On a price-to-earnings basis the stock looks elevated – approximately 80× trailing earnings, since 2025’s profit was modest (www.globenewswire.com). Yet traditional multiples are less meaningful for a nascent commercial biotech. Investors appear to be pricing in continued revenue growth and margin expansion as the PWS market further penetrates and as Soleno pursues new opportunities. Management is eyeing geographic and pipeline expansion: an EU marketing application for DCCR is underway, and the company plans to evaluate VYKAT XR in additional rare disorders to broaden its franchise (www.globenewswire.com). If VYKAT XR’s U.S. uptake accelerates again and ex-US or new indications come online, current multiples could moderate rapidly. Conversely, if safety issues cap adoption or prompt regulatory limits, Soleno’s rich valuation would be challenging to justify. Compared to other rare-disease drug developers, SLNO’s ~8× EV/revenue is in line with early commercial peers with monopolistic markets – a reflection of its first-mover advantage but also a premium at risk if the launch stumbles further.

Risks, Red Flags, and Open Questions

Safety and Efficacy Concerns: The foremost risk to Soleno is the safety profile of VYKAT XR in real-world use. The class action complaint and short-seller report both allege that Soleno concealed or downplayed significant safety issues observed in its clinical program (robbinsllp.com). In particular, fluid retention and edema in patients on DCCR were known side effects (seen in ~10% of trial participants) but may be linked to more severe cardiovascular outcomes than initially disclosed (robbinsllp.com). Scorpion Capital asserted there was a “rapid pile-up of reports of children hospitalized for potential heart failure” shortly after drug launch (www.prnewswire.com). Such incidents suggest VYKAT XR could pose greater risks to this fragile patient population (who often have cardiopulmonary vulnerabilities) than investors were led to believe. If ongoing pharmacovigilance uncovers additional cases of serious edema-related complications or other adverse events, regulators could intervene (e.g. adding strong warnings or restrictions). Soleno maintains that over four years of clinical data showed a “consistent safety profile” and manageable adverse reactions (investors.soleno.life), but the post-approval death of a patient in treatment (robbinsllp.com) has raised justifiable alarm. This September 2025 fatality – disclosed by Soleno in an SEC filing – is a glaring red flag. While details were not fully revealed, the event underscores that VYKAT XR’s risk/benefit balance may be narrower than anticipated, especially given PWS patients’ complex medical issues.

Launch Integrity and Data Questions: Beyond clinical risk, credibility of Soleno’s trial conduct and launch metrics has been challenged. The Scorpion report alleged that Soleno’s impressive early sales figures were partly “hocus-pocus,” driven heavily by one “controversial physician” in Gainesville, FL who led key trials and was presumably funneling numerous patients (via start forms) to the drug (www.prnewswire.com). This same investigator (presumably Dr. Jennifer Miller of U. Florida) also co-authored clinical papers on DCCR; Scorpion claims those publications “exhibit irregularities” and potential data integrity red flags (www.prnewswire.com). Such accusations, if proven, cast doubt on the reliability of Soleno’s Phase 3 results and even the FDA approval’s foundation. Open question: Did Soleno’s pivotal trial truly demonstrate VYKAT XR’s efficacy and safety for broad use, or was the data overly optimized by interested parties? The company vehemently described the drug’s clinical profile as favorable – citing 100+ patients on therapy over a year and some for 6+ years in its program (www.globenewswire.com) – and reported discontinuation rates for adverse events of around 12% (in line with expectations) (www.fool.com). However, investors must weigh the possibility that initial “exceeded expectations” launch results were not fully organic. If a large portion of early uptake came from a single center or was driven by aggressive advocacy, sustainable growth could be lower than it appeared. Prescriber trust is crucial; any hint of data manipulation or undisclosed risks can deter physicians from prescribing to vulnerable PWS patients.

Legal and Reputational Fallout: The current securities class action amplifies these issues by alleging that Soleno misled investors with rosy statements while withholding material problems (www.prnewswire.com). According to the complaint, management repeatedly touted that the launch was going “really well” and even “exceeded… expectations” (www.prnewswire.com) – statements that, in hindsight, look overly optimistic if not false. For example, just weeks before acknowledging the launch disruption, CEO Anish Bhatnagar extolled VYKAT’s “compelling efficacy and safety profile” and strong trajectory (www.globenewswire.com). Such comments, the lawsuit claims, were materially misleading given what the company allegedly knew about safety signals, patient drop-outs, and reliance on a narrow prescriber base (www.prnewswire.com). The class action (led by firms like Hagens Berman and Robbins LLP) consolidates investor grievances and will proceed through discovery, potentially bringing new information to light. While the outcome (and any financial penalties) will take time to resolve, the mere existence of the lawsuit is a reputational black eye. It may also consume management bandwidth at a time when focus on guiding the PWS community and ensuring patient safety is paramount. If evidence emerges that Soleno’s executives intentionally hid adverse data or exaggerated uptake, the trust damage could be lasting – not only with investors but with regulators and patient advocates. Moreover, the complaint explicitly warns that DCCR’s issues could lead to “adverse regulatory action” and “legal fallout” that jeopardize the drug’s commercial viability (robbinsllp.com). In sum, Soleno faces heightened scrutiny on all fronts.

Dependence on a Single Product: From an investment perspective, Soleno’s risk profile is heightened by its status as a one-product company. VYKAT XR is Soleno’s sole commercial asset (robbinsllp.com), meaning the company’s revenue, growth, and solvency all ride on this therapy’s success. PWS hyperphagia is a relatively small market – on the order of 8,000–12,000 patients in the U.S. – so ultimate sales are capped by disease prevalence. Soleno’s strategy to expand DCCR into new rare indications and geographic markets (EU, etc.) could eventually diversify revenues (www.globenewswire.com), but those are longer-term prospects subject to new R&D and regulatory hurdles. In the near term, any significant problem with VYKAT XR (be it a safety event, loss of physician confidence, or unfavorable insurance coverage decision) could severely undermine Soleno’s finances. The company’s hefty cash reserve provides a cushion, yet continued cash burn would resume if sales plateau or decline. Investors should note that Soleno already tapped equity markets for $230 million in mid-2025 (www.globenewswire.com) at high prices – a dilution that was acceptable when growth looked certain. If sentiment sours further, raising new equity capital would be far more dilutive. The $200 million debt facility, while currently underutilized, could also become a burden if cash flows weaken; it carries covenants and, eventually, substantial repayment obligations. All these factors mean Soleno has little room for error with VYKAT XR. It must execute almost flawlessly in navigating the safety concerns and convincing caregivers that benefits outweigh risks, or its rare success could turn into a cautionary tale.

Key Open Questions: Several critical questions remain unanswered as Soleno moves forward:

– Will ongoing post-marketing data uphold VYKAT XR’s safety profile, or will further serious adverse events (such as cardiac complications) emerge? Continuous data collection is vital to see if the early hospitalizations and the reported death were isolated incidents or indicative of a broader risk that could prompt an FDA safety alert or label change. – How will regulators in the U.S. and EU respond? The FDA will be monitoring adverse event reports; any trend could lead to additional warnings, a risk evaluation and mitigation strategy (REMS), or in extreme cases, suspension of marketing. European authorities, now reviewing DCCR, may delay or deny approval if concerns aren’t allayed. – Can Soleno’s management restore trust among physicians, patients, and investors? The PWS community is tight-knit – confidence in the therapy could falter if families fear safety issues or if they feel the company hasn’t been fully transparent. Investor confidence likewise hinges on clearer communication. The company’s next steps in addressing the short-seller allegations (e.g. through data transparency or independent analyses) will be closely watched. – Is Soleno’s growth trajectory still intact despite the hiccups? The company guided for adding ~1,000 new patient start forms over the next 9–12 months (www.fool.com). Achieving this will require re-accelerating prescriber adoption. One question is whether the initial bolus of patients (driven by high unmet need) has been largely tapped, with a slower uptake curve ahead – especially if some physicians adopt a “wait-and-see” stance due to safety headlines. Sustained growth may depend on converting skeptical prescribers and expanding awareness beyond early adopters. – What is the long-term legal and financial impact of the class action? While securities class actions often settle without crippling damages, this lawsuit could cost Soleno in legal fees and any settlement or judgment. Perhaps more importantly, discovery could keep negative news in headlines. Investors will want to know if any internal documents reveal warning signs that were omitted from public statements, as that could further damage management’s standing and even invite SEC inquiry.

In conclusion, Soleno Therapeutics finds itself at a crossroads. The company achieved what many small biotechs strive for – bringing a first-in-class drug to market and generating meaningful revenue – yet now faces a crisis of confidence. Its dividend policy is a non-issue (no dividends while growth is pursued), and its balance sheet remains strong for now, but valuation hinges on the resolution of current risks. SLNO’s story encapsulates both the promise and peril of biotech investing: a breakthrough for an unmet medical need, followed by unforeseen complications. Going forward, investors will be watching closely for any concrete evidence that VYKAT XR’s benefits can safely reach more patients, or conversely, any validation of the red flags raised. Until clarity emerges, this stock will likely trade more on clinical and legal news flow than on traditional fundamentals, making it a high-risk, high-reward equity that requires careful due diligence and monitoring of ongoing developments. (www.prnewswire.com) (robbinsllp.com)

For informational purposes only; not investment advice.